High materiality8/10
Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Stifel Nicolaus reiterates Buy on CLDX; target $68; posted price $33.57; price change since signal +0.54.
- Stifel reiterates Buy on CLDX
- Target $68 vs price $33.57
- Price change since signal: +0.54
Key facts
- 01
Target: $68
- 02
Posted price: $33.57
- 03
Analyst firm: Stifel Nicolaus
- 04
Analyst: Alex Thompson
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.